Clinical Trialblazers

How do you go from lawyer to biotech CEO? In this episode of Clinical Trialblazers, Heather Turner, CEO of LB Pharmaceuticals, shares her journey from legal counsel to leading a late-stage biotech company. She discusses the mindset shifts required to step into the CEO role, making high-stakes decisions with incomplete data, and balancing risk versus benefit. Heather brings more than 25 years of experience across biotech and life sciences, with a career that uniquely spans legal, operational, and executive leadership. We hope you enjoyed this week’s episode of Clinical Trialblazers. Please take a moment to rate and review this podcast wherever you listen. Special thanks to our production partner, Wonder Media Network. Our producer is Brittany Martinez, our editor is Gianna Palmer and our production assistant is Joia Putnoi.

Clinical Trialblazers is back for Season Two. Host Alberto Grignolo speaks with Paul Garofolo, Co-Founder and CEO of Locus Biosciences, about the leadership mindset behind capital efficiency, resource prioritization, and disciplined execution. Drawing on Paul’s journey from global leadership roles at Patheon to founding a next-generation precision medicine company, this episode explores fundraising across market cycles, founder-friendly capital, strategic and government partnerships, and the science behind Locus’ bacteriophage-based platform aimed at tackling multidrug-resistant infections.

In this season finale of Clinical Trialblazers, host Alberto Grignolo reflects on key insights and themes from conversations with biotech leaders over the past year. From researchers to entrepreneurs to investors, Alberto spoke with a wide range of leaders in the biotech industry, each with a unique perspective on the evolving biotech landscape and advice for aspiring innovators. This episode is just a sampling of the many compelling stories and lessons shared in this remarkable first season.

In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Miquel Vila-Perello, Ph.D. co-founder and CEO of SpliceBio, a gene therapy company focused on treating Stargardt disease. They discuss Miquel's journey from academia to biotech, the challenges of fundraising, the importance of passion and resilience in drug development, and the future of gene therapy. Miquel shares insights on balancing rationality and passion, the differences between academic and industry research, and the significance of building trust with investors.

In this episode of Clinical Trialblazers, Dr. Antti Vuolanto, CEO of Herantis Pharma Plc, shares his unconventional journey into the biotech industry, from bioengineering to leading a company focused on central nervous system (CNS) diseases. He discusses the scientific innovation behind HER096, a potential game-changer for Parkinson's disease, and the challenges of drug development. Beyond the science, Dr. Vuolanto offers profound lessons on the importance of building trust with colleagues and investors, the importance of taking risks, and the importance of work-life balance (a Finnish secret to happiness!). This episode highlights the power of mentorship, honest communication, and a deep commitment to impacting patients’ lives. He discusses the importance of mentorship, the challenges of drug development, and the significance of building trust with investors.

In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Dr. Sam Blackman, co-founder and former Chief Medical Officer of Day One Biopharmaceuticals, board member of the Pediatric Brain Tumor Foundation, Bonum Therapeutics and CureSearch for Children's Cancer, and the new Entrepreneur in Residence at Google Ventures. Sam talks about his career journey from physician to biotech executive, and navigating the complexities of clinical trials, especially within pediatric oncology. He also discusses the critical need to connect the science, patients, and investment thesis together into a coherent story when fundraising in drug development. 2:37 - How he was pulled to pediatric medicine 6:00 - His decision to transition into drug development to impact exponentially more patients. 16:40 - The importance of connecting you vision to your company name 26:04 - How making those risky decisions in drug development can have profound impacts on patient outcomes 40:00 - The Power of Storytelling in Science and Business 47:57 - Advice for biotech entrepreneurs seeking capital

In this episode of Clinical Trialblazers, host Alberto Grignolo speaks with Robert Blum, president and CEO of Cytokinetics, about his journey from the biology classroom to leading a biopharmaceutical company focused on muscle biology. Robert shares the values that guide his leadership style and how to move forward after failing.

Step inside the world of biotech leaders as they share the untold stories behind their journeys to bring breakthrough innovations to patients. Each episode uncovers the heart, grit, and ingenuity of the people shaping the future of scientific innovation—with Parexel as their trusted partner every step of the way. Host Alberto Grignolo – Editor-in-Chief of DIA Global Forum, a DIA podcast host, and a Fellow of DIA will sit down with biotech visionaries throughout 10 episodes to talk about the challenges they have faced, the pivotal moments that have shaped their careers and the lessons they have learned along the way. We hope you enjoyed this week’s episode of Clinical Trialblazers. Please take a moment to rate and review this podcast wherever you listen. Special thanks to our production partner, Wonder Media Network. Our producer is Brittany Martinez, our editor is Gianna Palmer and our production assistant is Joia Putnoi.